Femasys Inc. has doubled the number of clinical sites enrolling patients in its FemBloc FINALE pivotal trial across the U.S., expanding to twelve sites including top academic centers like Baylor and Columbia University. FemBloc is a non-surgical permanent birth control method designed to be done in an OB/GYN office without anesthesia or incisions, offering a safer, more affordable alternative to surgical sterilization. The trial aims to collect data on safety and effectiveness to support FDA approval, with an interim analysis planned after 300 women complete one year of use. This expansion marks significant progress in Femasys' U.S. regulatory strategy and global commercialization efforts following FemBloc's approval in Europe and other markets.
Femasys' FemBloc pivotal trial expansion is notable as the health sector on Pluang shows mixed activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 14, 2026 20:11 WIB: out of 150 priced US health stocks, 73 rose and 68 fell. Notable movers include BioNano Genomics Inc (BNGO) with a price of USD 1.39 and a 1-day change of +1.84%, Butterfly Network Inc (BFLY) at USD 7.95 down 1.85%, and Hims and Hers Health Inc (HIMS) at USD 29.20 down 1.72%, with varying Pluang order activity and typical hold times.
Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...
nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...
ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...
Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...
Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...
